Carisma Therapeutics, Inc. (CARM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Carisma Therapeutics, Inc. (CARM) trades at $0.01 with AI Score 61/100 (Grade B+). Carisma Therapeutics, Inc. is a biopharmaceutical company focused on developing CAR-macrophage therapies for solid tumors. Market cap: $246,886, Sector: Healthcare.
Price live · AI analysis from Jun 1, 2026Analyst Coverage for CARM: CARM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CARM against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CARM: 2/4 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Carisma Therapeutics, Inc. (CARM) Healthcare & Pipeline Overview
Carisma Therapeutics, Inc. pioneers CAR-macrophage therapies targeting solid tumors, differentiating itself through macrophage-based immunotherapy. With a strategic collaboration with Moderna, the company leverages its expertise in macrophage biology and CAR engineering to address unmet needs in cancer treatment within the competitive biotechnology sector.
What Is the Investment Thesis for CARM?
Carisma Therapeutics, Inc. presents a unique investment opportunity within the biotechnology sector, driven by its innovative CAR-macrophage technology. The company's strategic collaboration with Moderna provides validation and resources for clinical development. Key value drivers include successful clinical trial outcomes, regulatory approvals, and expansion of the CAR-macrophage platform to additional solid tumor targets. The company's high gross margin of 98.1% indicates strong potential for profitability upon commercialization. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established cancer therapies. Investors should monitor clinical trial data, regulatory milestones, and competitive dynamics to assess the long-term potential of Carisma Therapeutics, Inc.
Based on FMP financials and quantitative analysis
CARM Key Highlights
- Strategic collaboration with Moderna Inc. validates CAR-macrophage technology and provides resources for development.
- High gross margin of 98.1% suggests strong potential for profitability upon commercialization.
- Focus on CAR-macrophage therapies differentiates Carisma from competitors in the immunotherapy space.
- Based in Philadelphia, a hub for biotechnology innovation and research.
- Beta of 1.31 indicates higher volatility compared to the overall market.
Who Are CARM's Competitors?
CARM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| ZYME Zymeworks Inc. | $25.42 | -3.39% | $1.87B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CARM's Key Strengths?
- Innovative CAR-macrophage technology.
- Strategic collaboration with Moderna Inc.
- High gross margin potential.
- Experienced leadership team.
What Are CARM's Weaknesses?
- Early-stage clinical development.
- Dependence on clinical trial outcomes.
- Limited commercialization experience.
- Small company size.
What Could Drive CARM Stock Higher?
- Clinical trial data releases for CAR-macrophage therapies.
- Potential regulatory approvals from the FDA.
- Expansion of the CAR-macrophage platform to new tumor types.
- Strategic partnerships and collaborations with research institutions.
- Advancements in macrophage biology and CAR engineering.
What Are the Key Risks for CARM?
- Financial-distress signal — its Altman Z-Score of -45.88 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-28.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures and setbacks.
- Regulatory hurdles and delays.
- Competition from established cancer therapies.
- Dependence on clinical trial outcomes.
- Limited commercialization experience.
What Are the Growth Opportunities for CARM?
- Expansion of CAR-Macrophage Platform: Carisma has the opportunity to expand its CAR-macrophage platform to target additional solid tumor types. This includes exploring new CAR designs and target antigens to address a broader range of cancers. The market for targeted cancer therapies is expected to grow significantly, offering substantial revenue potential for Carisma as it broadens its pipeline. Timeline: Ongoing, with continuous research and development efforts.
- Advancement of Clinical Trials: Carisma's growth is heavily dependent on the successful advancement of its clinical trials. Positive data from Phase 1 and Phase 2 trials could lead to accelerated regulatory approval and commercialization. The market for successful cancer therapies is substantial, with potential blockbuster drugs generating billions in annual revenue. Timeline: Anticipated within the next 2-3 years.
- Strategic Partnerships and Collaborations: Carisma can leverage strategic partnerships and collaborations to accelerate its research and development efforts. Collaborating with leading research institutions and pharmaceutical companies can provide access to new technologies, funding, and expertise. The value of such partnerships can range from millions to billions of dollars, depending on the scope and potential of the collaboration. Timeline: Ongoing.
- Regulatory Approvals and Commercialization: Obtaining regulatory approvals from the FDA and other regulatory agencies is crucial for Carisma's growth. Successful commercialization of its CAR-macrophage therapies would generate significant revenue and establish Carisma as a leader in the immunotherapy space. The market for approved cancer therapies is highly lucrative, with potential for rapid market penetration. Timeline: Anticipated within the next 3-5 years.
- Intellectual Property Protection: Strengthening its intellectual property portfolio is essential for Carisma to maintain a competitive advantage. Securing patents for its CAR-macrophage technology and related innovations will protect its market position and attract potential investors. The value of a strong IP portfolio can significantly enhance the company's valuation and long-term growth prospects. Timeline: Ongoing.
What Opportunities Does CARM Have?
- Expansion of CAR-macrophage platform to new tumor types.
- Partnerships with leading research institutions.
- Accelerated regulatory approval pathways.
- Growing market for cancer immunotherapies.
What Threats Does CARM Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established cancer therapies.
- Patent disputes.
What Are CARM's Competitive Advantages?
- Proprietary CAR-macrophage technology platform.
- Strategic collaboration with Moderna Inc.
- Expertise in macrophage biology and CAR engineering.
- Strong intellectual property portfolio.
What Does CARM Do?
Carisma Therapeutics, Inc., founded in 2016 and based in Philadelphia, is a biopharmaceutical company dedicated to developing innovative cancer therapies. The company specializes in chimeric antigen receptor (CAR) macrophages, a novel approach to treating solid tumors. Carisma's technology harnesses the innate and adaptive immune response by leveraging advances in macrophage biology, CAR engineering, and adoptive cellular therapy. Macrophages, crucial components of the immune system, are engineered to express CARs, enabling them to specifically target and destroy cancer cells. This approach aims to overcome the limitations of traditional cancer treatments by enhancing the body's natural ability to fight tumors. Carisma's lead product candidates are designed to address a range of solid tumors, offering potential solutions for patients with limited treatment options. The company has a strategic collaboration agreement with Moderna Inc., further validating its technology and providing resources for development and clinical trials. Carisma Therapeutics, Inc. operates primarily in the United States, focusing on research, development, and clinical advancement of its CAR-macrophage platform.
What Products and Services Does CARM Offer?
- Develops chimeric antigen receptor (CAR) macrophages for solid tumor treatment.
- Engineers macrophages to target and destroy cancer cells.
- Leverages macrophage biology and CAR engineering for immunotherapy.
- Conducts research and development to advance its CAR-macrophage platform.
- Collaborates with Moderna Inc. on therapeutic development.
- Focuses on addressing unmet needs in cancer treatment.
How Does CARM Make Money?
- Develops and patents CAR-macrophage technology.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its therapies.
- Seeks regulatory approvals from agencies like the FDA.
- Commercializes approved therapies through direct sales or partnerships.
What Industry Does CARM Operate In?
Carisma Therapeutics, Inc. operates within the rapidly evolving biotechnology industry, specifically in the field of immunotherapy. The market for cancer therapies is substantial and growing, driven by increasing cancer incidence and advancements in treatment options. The competitive landscape includes established pharmaceutical companies and emerging biotech firms developing various immunotherapies, such as CAR-T cell therapy and checkpoint inhibitors. Carisma's CAR-macrophage approach offers a differentiated strategy by leveraging the unique properties of macrophages to target solid tumors. The global immunotherapy market is projected to reach billions of dollars by 2030, highlighting the significant growth potential for companies like Carisma Therapeutics, Inc.
Who Are CARM's Key Customers?
- Patients with solid tumors who have limited treatment options.
- Hospitals and cancer centers that administer CAR-macrophage therapies.
- Pharmaceutical companies seeking to collaborate on cancer treatment development.
Carisma Therapeutics, Inc. Financial Trajectory
Carisma Therapeutics, Inc. (CARM) reported $45.3M in revenue for Q3 2025, reflecting 1113.5% growth compared to the prior quarter. The company recorded net income of $44.7M, with diluted EPS of $1.07. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company.
Company Profile
Carisma Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Philadelphia, US. The company is led by CEO Saar Gill. CARM has traded publicly since 2014.
How Carisma Therapeutics, Inc. Is Valued
Carisma Therapeutics, Inc. carries a market capitalization of 247K, placing it in the micro-cap category. Relative to its peer group, CARM's quantitative score of 61/100 is below the peer average of 76/100.
ROE -29%Key Financial Metrics
Return on equity for Carisma Therapeutics, Inc. stands at -28.9%, a gauge of how efficiently it converts shareholder capital into profit. CARM trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. A current ratio of 0.86 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 3/9Financial Health
Carisma Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -45.88 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Carisma Therapeutics, Inc. revenue of about $9.1M for fiscal 2026, with EPS near $-0.52.
CARM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Innovative CAR-macrophage technology.
- Strategic collaboration with Moderna Inc.
- High gross margin potential.
- Experienced leadership team.
Bear Case
- Early-stage clinical development.
- Dependence on clinical trial outcomes.
- Limited commercialization experience.
- Small company size.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $45M | $45M | $1.07 |
| Q1 2025 | $4M | -$9M | -$0.22 |
| Q4 2024 | $4M | -$18M | -$0.42 |
Based on FMP financials and quantitative analysis
CARM Latest News
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Mar 16, 2023
CARM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CARM.
Price Targets
Wall Street price target analysis for CARM.
CARM MoonshotScore
What does this score mean?
The MoonshotScore rates CARM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Saar Gill
CEO
Saar Gill is the CEO of Carisma Therapeutics, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has a strong track record in leading and growing innovative companies focused on developing novel therapies. His expertise spans across research and development, clinical trials, and commercialization strategies. He is responsible for managing 46 employees.
Track Record: Under Saar Gill's leadership, Carisma Therapeutics, Inc. has achieved significant milestones in advancing its CAR-macrophage platform. He has overseen the company's strategic collaboration with Moderna Inc. and guided the progress of its clinical trials. His strategic decisions have positioned Carisma as a leader in the development of CAR-macrophage therapies.
CARM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Carisma Therapeutics, Inc. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, may be thinly traded, and are subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Less regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Strategic collaboration with Moderna Inc.
- Focus on innovative CAR-macrophage technology.
- Experienced leadership team.
- Presence in the biotechnology sector.
What Investors Ask About Carisma Therapeutics, Inc. (CARM) — Healthcare
What does Carisma Therapeutics, Inc. do?
Carisma Therapeutics, Inc. is a biopharmaceutical company focused on developing a novel immunotherapy approach using chimeric antigen receptor (CAR) macrophages to treat solid tumors. Their technology engineers macrophages, a type of immune cell, to express CARs that specifically target and destroy cancer cells. This innovative approach aims to overcome the limitations of traditional cancer treatments by enhancing the body's natural ability to fight tumors, potentially offering new treatment options for patients with limited alternatives.
What do analysts say about CARM stock?
Analyst coverage of Carisma Therapeutics, Inc. is limited due to its OTC listing and early stage of development. However, analysts generally view the company's CAR-macrophage technology as promising, given its potential to address unmet needs in solid tumor treatment. Key valuation metrics include the potential market size for CAR-macrophage therapies and the company's ability to secure regulatory approvals and commercialize its products. Growth considerations include the successful advancement of clinical trials and the expansion of the CAR-macrophage platform to new tumor types.
What are the main risks for CARM?
The main risks for Carisma Therapeutics, Inc. include clinical trial failures, regulatory hurdles, and competition from established cancer therapies. Clinical trial failures could significantly impact the company's valuation and future prospects. Regulatory hurdles, such as delays in obtaining FDA approval, could also delay the commercialization of its therapies. Competition from established cancer therapies, such as chemotherapy and radiation, as well as other immunotherapies, could limit the market share and revenue potential of Carisma's products.
What are the key factors to evaluate for CARM?
Carisma Therapeutics, Inc. (CARM) holds an AI score of 61/100 (moderate). P/E: 0.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CARM data refresh on this page?
CARM prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CARM's recent stock price performance?
Carisma Therapeutics, Inc. (CARM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative CAR-macrophage technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CARM overvalued or undervalued right now?
Carisma Therapeutics, Inc. (CARM) trades at 0.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CARM?
Before investing in Carisma Therapeutics, Inc. (CARM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be as comprehensive as for companies listed on major exchanges.